AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 122 min read$MNPR

Monopar Therapeutics (MNPR): Results of Operations and Financial Condition

Monopar Therapeutics (MNPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. mnpr20260811_8k.htm false 0001645469 0001645469 2026-08-12 2026-08-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo

Original reporting
SEC EDGAR 8-K
Published Aug 12, 2026, 1:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 1:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$MNPR
Neutral
low confidence
Mentioned
$MNPR
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MNPRNeutralLow
01

Why it matters

Traders should treat this as the official release vehicle for Q2 results; however, the excerpt does not provide the figures needed to judge whether the report is a beat, miss, or includes updated outlook.

02

Market read

This filing is the mechanism for Q2 results dissemination, but the excerpt lacks the quantitative content that typically drives trading decisions.

03

What to watch

Key drivers likely include cash runway, operating expense trajectory, and any updated pipeline or commercialization commentary, none of which are present in the provided text.

Relevance 7/10Novelty 3/10Timing: Filed pre-market/at 09:30:54 ET on Aug 12, 2026 with Q2 results press release furnished as Exhibit 99.1.

Background

The company furnished an 8-K under Item 2.02 to report its financial results for the second quarter ended June 30, 2026, attaching a press release as Exhibit 99.1.

Company-level read

Ticker impact

$MNPRNeutralLow confidence
Context

Monopar filed an 8-K furnishing its Q2 2026 results press release for the quarter ended June 30, 2026.

Expected impact

Near-term volatility possible on release day, but direction cannot be inferred from the provided excerpt.

Evidence & confidence

The filing confirms the company issued Q2 2026 results via Exhibit 99.1, yet the excerpt contains no revenue, EPS, cash, or outlook numbers to assess beat/miss or changes.

Market effects

Sector

No sector read-through is provided in the excerpt beyond routine quarterly reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Without the actual Q2 numbers or guidance in the excerpt, the market reaction may be driven by details not captured here, so traders should verify Exhibit 99.1 before trading.

Key entities

  • company
    Monopar Therapeutics Inc.

    Nasdaq-listed issuer that furnished its Q2 2026 results press release via 8-K Item 2.02.

  • person
    Quan Vu

    Chief Financial Officer who signed the 8-K.

Read at source← All news

Related articles

JUN 1
$MNPRMedAI 8/10

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics presented Phase 2 ALXN1840 (tiomolibdate choline) data at EASL 2026 for treatment-experienced Wilson disease patients. In an open-label, multicenter 48-week trial (29 patients; 24 with paired biopsies), histology showed stabilization or improvement in multiple liver measures, with no statistically significant change in hepatic copper. The company also reported significant improvements in UWDRS Part III, CGI, and EQ-5D UK, with generally nonserious Grade 1–2 adverse events.

manilatimes.net4 min
AUG 12
$NEONMed

Neonode Inc. (NEON): Results of Operations and Financial Condition

Neonode Inc. (NEON) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_975142.htm EXHIBIT 99.1 ex_975142.htm Exhibit 99.1 Press Release For Release, 9:10AM ET August 12, 2026 Neonode Reports Quarter Ended June 30, 2026 Financial Results STOCKHOLM, SWEDEN, August 12, 2026 — Neonode Inc. (NASDAQ: NEON) (“Neonode” or the “Company”) today r

SEC EDGAR 8-K4 min
AUG 12
$CAPSMed

Capstone Holding Corp. (CAPS): Results of Operations and Financial Condition

Capstone Holding Corp. (CAPS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_1003476.htm EXHIBIT 99.1 ex_1003476.htm Exhibit 99.1 Capstone Reports Q2 2026 Results: Revenue Up 67%, Gross Profit Up 92%, Stone Business Adjusted EBITDA Turns Positive as Guided Stone Business Adjusted EBITDA of $2.0 million at a 9.4% margin delivers the second-qua

SEC EDGAR 8-K4 min
AUG 12
$SPRBMed

SPRUCE BIOSCIENCES, INC. (SPRB): Results of Operations and Financial Condition

SPRUCE BIOSCIENCES, INC. (SPRB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 sprb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Biologics License Application (BLA) for TA-ERT for the Treatment of MPS IIIB Anticipated in the Fourth Quarter of 2026 TrAnsform

SEC EDGAR 8-K6 min
Monopar Therapeutics (MNPR): Results of Operations and Financial Condition — alphai